# Perioperative Heparin Bridging in Patients With Mechanical Aortic Valves Undergoing Elective Surgery: The AMBER Study

**Authors:** Alejandro Godoy, Tegvir S. Grewal, Vinai Bhagirath, Alfonso Tafur, Amelia McNiven Fontani, Ana I. Casanegra, Atefeh Ghorbanzadeh, Damon E. Houghton, Jameel Abdulrehman, Jean-Philippe Galanaud, Karen Sidhom, Luigi Del Sordo, Mouza Alnuaimi, Paul R. Daniels, Stephanie Carlin, Yama Sadozai, Alex Spyropoulos, James Douketis

PMC · DOI: 10.1016/j.jacadv.2025.102578 · JACC: Advances · 2026-01-23

## TL;DR

A study found that using heparin to prevent blood clots in heart valve patients during surgery does not reduce clot risk but increases bleeding.

## Contribution

The study provides real-world evidence that full heparin bridging increases bleeding risk without preventing thromboembolism in mechanical aortic valve patients.

## Key findings

- Thromboembolic events were rare (<0.5%) and similar across all bridging strategies.
- Full bridging was associated with significantly higher major bleeding rates (3.0% vs 0%).

## Abstract

The benefit–risk balance of perioperative low-molecular-weight heparin (LMWH) bridging in patients with bileaflet mechanical aortic valves undergoing elective procedures is uncertain. While intended to prevent thromboembolism during warfarin interruption, LMWH may increase bleeding risk without a proven efficacy benefit.

This study aimed to evaluate the rates of thromboembolism and bleeding associated with different peri-operative LMWH bridging strategies compared to no bridging in this patient population.

In a multicenter retrospective cohort study, 553 patients requiring warfarin interruption were classified into 3 main analysis groups: preoperative and postoperative LMWH (n = 232), preoperative-only LMWH (n = 81), postoperative-only LMWH (n = 33), and no bridging (n = 207). The primary efficacy outcome was arterial thromboembolism within 30 days. Primary and secondary safety outcomes were major bleeding and clinically relevant non-major bleeding. Outcomes were analyzed with multivariable logistic regression and propensity-matched comparisons.

Thromboembolic events were rare (<0.5%) and similar across all strategies. Compared to no bridging, full bridging was associated with significantly higher rates of major bleeding (3.0% vs 0%; P = 0.018) and any clinically relevant bleeding (9.5% vs 2.0%; P < 0.01). In multivariable models, full bridging predicted bleeding, whereas preoperative-only bridging did not. In a propensity-matched analysis, full bridging remained associated with a higher risk of any clinically relevant bleeding (10.6% vs 2.4%; P < 0.01).

Among patients with bileaflet mechanical aortic valves undergoing elective procedures, 30-day thromboembolic events were rare. Full perioperative LMWH bridging was associated with increased bleeding. While this study provides valuable real-world data, prospective clinical trials are necessary to confirm and expand upon these findings.

## Linked entities

- **Chemicals:** warfarin (PubChem CID 54678486)

## Full-text entities

- **Diseases:** Thrombosis and Haemostasis (MESH:D020141), Arterial (MESH:D012078), pulmonary embolism (MESH:D011655), Bleeding (MESH:D006470), Venous thromboembolism (MESH:D054556), MHV (MESH:D006349), coagulation abnormalities (MESH:D001778), systemic embolism (MESH:D004617), deep vein thrombosis (MESH:D020246), CRNMB (MESH:D004830), hypertension (MESH:D006973), ischemic stroke (MESH:D002544), kidney infarction (MESH:D007680), infarction (MESH:D007238), Thrombosis (MESH:D013927), Thromboembolic (MESH:D013923), stroke (MESH:D020521), acute limb ischemia (MESH:D000208), CKD (MESH:D051436), TIA (MESH:D002546), death (MESH:D003643), bowel ischemia (MESH:D007511), Congestive heart failure (MESH:D006333), AF (MESH:D001281)
- **Chemicals:** vitamin K antagonist (-), dalteparin (MESH:D017985), Heparin (MESH:D006493), Warfarin (MESH:D014859), enoxaparin (MESH:D017984), LMWH (MESH:D006495), tinzaparin (MESH:D000078222)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12860947/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12860947/full.md

## References

15 references — full list in the complete paper: https://tomesphere.com/paper/PMC12860947/full.md

---
Source: https://tomesphere.com/paper/PMC12860947